Iguratimod Combined With Tofacitinib in the Treatment of Rheumatoid Arthritis
Status:
Not yet recruiting
Trial end date:
2025-12-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy and safety of Iguratimod combined with
Tofacitinib in the treatment of csDMARD-IR patients with active moderate-to-severe rheumatoid
arthritis